Citation Impact
Citing Papers
Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
2009
Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
2008
Circulating microRNAs as stable blood-based markers for cancer detection
2008 Standout
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
Anaesthesia, surgery, and challenges in postoperative recovery
2003 Standout
Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer
2000
Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY
1996
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Regulation of the Voltage Gated K<sup>+</sup> Channel K<sub>v1.3</sub> by Recombinant Human Klotho Protein
2014 Standout
Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid: Preliminary results
1997
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling
2015
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines
2010
Voltage-sensitive ion channels and cancer
2006
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells
2004
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer
1999
Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance
2003
Clinical aspects of altered glycosylation of glycoproteins in cancer
1999
Differential PTEN Protein Expression Profiles in Superficial versus Invasive Bladder Cancers
2005
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
2003 Standout
Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression
2002
Solid lipid nanoparticles Production, characterization and applications
2001 Standout
Clinical Relevance of Ion Channels for Diagnosis and Therapy of Cancer
2005
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy
2010
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Mucins in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Implications
2014
Androgen Receptor Gene Alterations in Finnish Male Breast Cancer
2003
Bladder cancer
2016 Standout
Male breast cancer
2006 Standout
THE NATURAL HISTORY OF BLADDER CANCER
2000
A new human prostate carcinoma cell line, 22Rv1
1999
Photodynamic therapy and anti-tumour immunity
2006 Standout
The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder
1998 Standout
Linking β-Catenin to Androgen-signaling Pathway
2002
Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility
2011
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer
1994
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
2003 Standout
Initial Evaluation and Response Criteria for Patients with Superficial Bladder Cancer
1990
Three‐year Follow‐up of Bladder Tumours found on Screening
1993
Chemistry in living systems
2005 StandoutNobel
Paradoxical roles of the immune system during cancer development
2006 Standout
Urothelial Transitional Cell Carcinoma with Endophytic Growth Patterns
1997
The voltage-dependent K+ channels Kv1.3 and Kv1.5 in human cancer
2013
The Ki-67 protein: From the known and the unknown
2000 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas
2001 StandoutNobel
PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells
2010
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells
2005 StandoutNobel
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
2001 StandoutNature
Controlling Cell Behavior Electrically: Current Views and Future Potential
2005 Standout
MHC antigens and tumor escape from immune surveillance
2001
Metabolic selection of glycosylation defects in human cells
2001 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Maftools: efficient and comprehensive analysis of somatic variants in cancer
2018 Standout
Cyclooxygenases in cancer: progress and perspective
2004
Cyclooxygenase-2 and prostate carcinogenesis
2003
The Polycomb complex PRC2 and its mark in life
2011 StandoutNature
Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
2002
Tumorigenesis and the angiogenic switch
2003 Standout
Matrix Metalloproteinases
1999 Standout
The pathology of bladder cancer
2006
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
2004
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
Relationship between Schistosomiasis and Bladder Cancer
1999
Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts
1998
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
1996
Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues
1990
The Three Es of Cancer Immunoediting
2004 Standout
Effect of laparoscopy on immune function
2001
Keratoconus and related noninflammatory corneal thinning disorders
1984 Standout
Heat shock protein expression independently predicts clinical outcome in prostate cancer.
2000
Recurrence of high‐risk bladder cancer: A population‐based analysis
2013
Cellular Proliferative Fraction of Metastatic Lymph Nodes Predicts Survival in Stage D1 (TxN+MO) Prostate Cancer
1996
Bladder Cancer
2020 Standout
Sigma Receptors and Cancer
2004
Grading of Human Urothelial Carcinoma Based on Nuclear Atypia and Mitotic Frequency. II. Histological Description
1991
PROGNOSTIC FACTORS OF OUTCOME AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER: A RETROSPECTIVE STUDY OF A HOMOGENEOUS PATIENT COHORT
1999
A Community Study of Bladder Cancer Screening by the Detection of Occult Urinary Bleeding
1992
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
2002 StandoutNobel
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
1997
Directional movement of rat prostate cancer cells in direct-current electric field
2001
Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer.
2003
Cell Proliferation Assessed by Ki-67 Immunoreactivity on Formalin Fixed Tissues is a Predictive Factor for Survival in Prostate Cancer
1997
Bladder tumours detected on screening: results at 7 years
1998
Cancer treatment and survivorship statistics, 2019
2019 Standout
Ocular Rigidity in Keratoconus
1978
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Ki-67 Expression is a Prognostic Marker of Prostate Cancer Recurrence after Radical Prostatectomy
1996
Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease
2004
Gene-based vaccines and immunotherapeutics
2004
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLY
1998
Reproducibility and Prognostic Variability of Grade and Lamina Propria Invasion in Stages Ta, T1 Urothelial Carcinoma of the Bladder
2003
Inverse Relationship Between Skp2 Ubiquitin Ligase and the Cyclin Dependent Kinase Inhibitor p27 Kip1 in Prostate Cancer
2003 StandoutNobel
Predicting Cancer Progression in Patients With Stage T1 Bladder Carcinoma
1999
Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses
2005 StandoutNobel
Works of P D Abel being referenced
Second messenger up‐regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC‐3 and DU‐145
1996
Differing Interpretations by Pathologists of the pT Category and Grade of Transitional Cell Cancer of the Bladder
1988
Expression of bcl‐2 and p53 oncoproteins in schistosomiasis‐associated transitional and squamous cell carcinoma of urinary bladder
1997
Cytoplasmic induction and over‐expression of cyclooxygenase‐2 in human prostate cancer: implications for prevention and treatment
2000
Follow‐up of Patients with “Superficial” Transitional Cell Carcinoma of the Bladder: the Case for a Change in Policy
1993
Differential expression of voltage‐activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro
1995
Phenotypic and genotypic characterization of commonly used human prostatic cell lines
2000
Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer
1989
Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic Carcinoma
1993
Pituitary Adrenal and Gonadal Endocrine Suppression for the Primary Treatment of Prostate Cancer
1990
Three‐monthly GnRH Agonist (Buserelin) for Prostatic Cancer
1990
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastics and malignant human prostatic epithelium
1994
Should pT1 Transitional Cell Cancers of the Bladder still be Classified as Superficial?
1988
Keratoconus and contact lenses.
1963
Prognostic Indices in Transitional Cell Carcinoma of the Bladder
1988
Peritoneal and systemic cytokine response to laparotomy
1996
Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro.
1997
Assessment of Serum CA 19.9 as a Tumour Marker in Patients with Carcinoma of the Bladder and Prostate
1987